Literature DB >> 17445908

The new GRID Hamilton Rating Scale for Depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training.

Hideaki Tabuse1, Amir Kalali, Hideki Azuma, Norio Ozaki, Nakao Iwata, Hiroshi Naitoh, Teruhiko Higuchi, Shigenobu Kanba, Kunihiko Shioe, Tatsuo Akechi, Toshi A Furukawa.   

Abstract

The Hamilton Rating Scale for Depression (HAMD) is the de facto international gold standard for the assessment of depression. There are some criticisms, however, especially with regard to its inter-rater reliability, due to the lack of standardized questions or explicit scoring procedures. The GRID-HAMD was developed to provide standardized explicit scoring conventions and a structured interview guide for administration and scoring of the HAMD. We developed the Japanese version of the GRID-HAMD and examined its inter-rater reliability among experienced and inexperienced clinicians (n=70), how rater characteristics may affect it, and how training can improve it in the course of a model training program using videotaped interviews. The results showed that the inter-rater reliability of the GRID-HAMD total score was excellent to almost perfect and those of most individual items were also satisfactory to excellent, both with experienced and inexperienced raters, and both before and after the training. With its standardized definitions, questions and detailed scoring conventions, the GRID-HAMD appears to be the best achievable set of interview guides for the HAMD and can provide a solid tool for highly reliable assessment of depression severity.

Entities:  

Mesh:

Year:  2007        PMID: 17445908     DOI: 10.1016/j.psychres.2006.07.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

1.  Transcultural Adaptation of GRID Hamilton Rating Scale For Depression (GRID-HAMD) to Brazilian Portuguese and Evaluation of the Impact of Training Upon Inter-Rater Reliability.

Authors:  Ricardo Henrique-Araújo; Flávia L Osório; Mônica Gonçalves Ribeiro; Ivandro Soares Monteiro; Janet B W Williams; Amir Kalali; José Alexandre Crippa; Irismar Reis De Oliveira
Journal:  Innov Clin Neurosci       Date:  2014-07

Review 2.  The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder.

Authors:  Anthony L Vaccarino; Kenneth R Evans; Amir H Kalali; Sidney H Kennedy; Nina Engelhardt; Benicio N Frey; John H Greist; Kenneth A Kobak; Raymond W Lam; Glenda MacQueen; Roumen Milev; Franca M Placenza; Arun V Ravindran; David V Sheehan; Terrence Sills; Janet B W Williams
Journal:  Innov Clin Neurosci       Date:  2016-10-01

3.  Influence of comorbid alcohol use disorder on treatment response of depressive patients.

Authors:  Eri Hashimoto; Masaya Tayama; Hiromi Ishikawa; Megumi Yamamoto; Toshikazu Saito
Journal:  J Neural Transm (Vienna)       Date:  2014-06-14       Impact factor: 3.575

4.  Cost-effectiveness analyses of augmented cognitive behavioral therapy for pharmacotherapy-resistant depression at secondary mental health care settings.

Authors:  Mitsuhiro Sado; Akihiro Koreki; Akira Ninomiya; Chika Kurata; Dai Mitsuda; Yasunori Sato; Toshiaki Kikuchi; Daisuke Fujisawa; Yutaka Ono; Masaru Mimura; Atsuo Nakagawa
Journal:  Psychiatry Clin Neurosci       Date:  2021-09-17       Impact factor: 12.145

5.  Increased cerebrospinal fluid fibrinogen in major depressive disorder.

Authors:  Kotaro Hattori; Miho Ota; Daimei Sasayama; Sumiko Yoshida; Ryo Matsumura; Tomoko Miyakawa; Yuuki Yokota; Shinobu Yamaguchi; Takamasa Noda; Toshiya Teraishi; Hiroaki Hori; Teruhiko Higuchi; Shinichi Kohsaka; Yu-ichi Goto; Hiroshi Kunugi
Journal:  Sci Rep       Date:  2015-06-17       Impact factor: 4.379

6.  Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study): study protocol for a randomised clinical trial.

Authors:  Atsuo Nakagawa; Mitsuhiro Sado; Dai Mitsuda; Daisuke Fujisawa; Toshiaki Kikuchi; Takayuki Abe; Yuji Sato; Satoru Iwashita; Masaru Mimura; Yutaka Ono
Journal:  BMJ Open       Date:  2014-10-21       Impact factor: 2.692

7.  Cognitive behavioral therapy for depression in Japanese Parkinson's disease patients: a pilot study.

Authors:  Issei Shinmei; Kei Kobayashi; Yuki Oe; Yuriko Takagishi; Ayako Kanie; Masaya Ito; Yoshitake Takebayashi; Miho Murata; Masaru Horikoshi; Roseanne D Dobkin
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-08       Impact factor: 2.570

8.  Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP study): study protocol for a randomized controlled trial.

Authors:  Masaya Ito; Yasuyuki Okumura; Masaru Horikoshi; Noriko Kato; Yuki Oe; Mitsuhiro Miyamae; Naotsugu Hirabayashi; Ayako Kanie; Atsuo Nakagawa; Yutaka Ono
Journal:  BMC Psychiatry       Date:  2016-03-18       Impact factor: 3.630

9.  The efficacy of interpersonal psychotherapy for depression among economically disadvantaged mothers.

Authors:  Sheree L Toth; Fred A Rogosch; Assaf Oshri; Julie Gravener-Davis; Robin Sturm; Antonio Alexander Morgan-López
Journal:  Dev Psychopathol       Date:  2013-11

10.  Serum BDNF levels before and after the development of mood disorders: a case-control study in a population cohort.

Authors:  K Ihara; H Yoshida; P B Jones; M Hashizume; Y Suzuki; H Ishijima; H K Kim; T Suzuki; M Hachisu
Journal:  Transl Psychiatry       Date:  2016-04-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.